Skip to content

Loop Diuretics in Chronic Kidney Disease

Effect of Loop Diuretics Treatment on Blood Pressure Control in Phase 3-4 of Chronic Kidney Disease

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00478543
Enrollment
40
Registered
2007-05-25
Start date
2005-09-30
Completion date
2008-07-31
Last updated
2009-02-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Kidney Disease

Keywords

Loop diuretics, Chronic Kidney Disease, Hypertension, Blood pressure control, Left ventricular mass

Brief summary

The purpose of this study is to verify the efficacy of diuretic therapy on blood pressure control and left ventricular mass in patients affected by chronic kidney disease

Detailed description

In CKD, impairment of renal function causes fluid and sodium retention and consequently expansion of extracellular volume, which corresponds to about 5% of body weight in absence of peripheral edema. In particular, sodium retention increases exponentially as glomerular filtration rate declines and is of primary importance in the pathogenesis of hypertension. Therefore, reduction of salt intake in renal patients allows a better blood pressure control. Despite the evidence collected on the beneficial effects of salt restriction in CKD, compliance with dietary prescription is generally poor in patients followed up in the real world of clinical practice. In the presence of poor adherence to salt restriction, diuretics agents become the cornerstone of treatment of hypertension secondary to CKD. Disappointingly, nephrologists are reluctant to adequately use loop diuretics in their hypertensive CKD patients, probably because of the fear of side effects and of the amazing absence in medical literature of studies of middle-long term on diuretic efficacy. Therefore, the primary aim of this study is to evaluate efficacy and safety of loop diuretics on blood pressure control in patients affected by CKD.

Interventions

DRUGFurosemide

Sponsors

University of Campania Luigi Vanvitelli
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Chronic renal insufficiency in stage CKD 3 and 4 (GFR 60-15 ml/min/m2) estimated by Cockcroft-Gault formula corrected for body surface * Systolic blood pressure \>140 mmHg in treatment with at least 1 class of antihypertensive drugs * Patients not in treatment from at least one month with loop diuretics

Exclusion criteria

* Loop diuretics treatment * Variation of serum creatinine \>30% in the last 3 months * Steroid therapy and/or cytotoxic agents * Edema syndromes (Nephrotic syndrome, cirrhosis, heart failure NYHA class 3 or 4) * Neoplasia

Design outcomes

Primary

MeasureTime frame
Attainment of blood pressure target (<130/80 mmHg)and evaluation of left ventricular mass by echocardiography6 months and 1 year respectively

Secondary

MeasureTime frame
Adverse drug reactions, ambulatory blood pressure measure control, body volumes evaluated by bioimpedance analysis, expense of time and resources in follow-up of patients6 months

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026